SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 8th, 2024 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 4, 2024, between SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc.SELLAS Life Sciences Group, Inc. • January 8th, 2024 • Pharmaceutical preparations
THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January [*], 20291 (the “Termination Date”) but not thereafter, to subscribe for and purchase from SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), up to ______ shares of Common Stock, par value $0.0001 per share (the “Common Stock”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ContractSELLAS Life Sciences Group, Inc. • January 8th, 2024 • Pharmaceutical preparations • New York
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer
